India's widening goods trade deficit in October has raised concerns among analysts, with Nuvama Research highlighting that the country's rising gold imports must be closely watched to assess the future trade deficit trajectory.
Office space demand in India is expected to strengthen as the conversion of Special Economic Zone (SEZ) areas into regular office spaces gathers momentum, according to a report by Nuvama Research.
India's power demand slumped 5.2 per cent year-on-year in October 2025, dragged down by unseasonal rainfall and lower temperatures that reduced the need for cooling loads, according to a power sector update by Nuvama Research
The automobile sector is expected to record strong year-on-year growth in sales across all segments in September, supported by festive demand and positive customer sentiment, according to a report by Nuvama Research.
The sharp rise in housing prices seen over the past two years is expected to moderate, according to a sectoral analysis by Nuvama Institutional Equities. The brokerage said that the Indian real estate cycle has entered its mid-stage, where buying frenzy is easing, sales velocity is slowing,
The pipe industry in the country is expected to witness subdued growth in the first quarter of financial year 2025-26 (Q1FY26), according to a report by Nuvama Research.
The coal output in the country is expected to decline further in June as demand remained muted across several regions during the pre-monsoon season, according to a report by Nuvama Research.
India's infrastructure sector witnessed a mixed performance in the fourth quarter of FY25, with revenues and profit margins under pressure despite improvement in order inflows, according to a report by Nuvama Research.
The profit growth of Indian companies slowed down in the financial year 2024-25, as soft demand, weak top-line performance, and slowing capital expenditure weighed on overall corporate performance, says a report by Nuvama Research.
The outlook for the Indian cement sector is improving as both demand and prices are likely to rise in the coming months, according to a report by Nuvama Research.
The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for Indian pharmaceutical companies, especially those operating in the U.S. generic drug market, according to a report by Nuvama Research.